Michael C. Veronesi MD, PhD, Presenter: Nothing to Disclose

Shih-Hsun Cheng PhD, Abstract Co-Author: Nothing to Disclose

Hsiu-Ming Tsai PhD, Abstract Co-Author: Nothing to Disclose

Hannah J. Zhang PhD, Abstract Co-Author: Nothing to Disclose

Marta A. Zamora BS, Abstract Co-Author: Nothing to Disclose

James Vosicky, Abstract Co-Author: Nothing to Disclose

Devkumar Mustafi PhD, Abstract Co-Author: Nothing to Disclose

Xiaobing Fan PhD, Abstract Co-Author: Nothing to Disclose

Leuwei Lo PhD, Abstract Co-Author: Nothing to Disclose

Chin-Tu Chen PhD, Abstract Co-Author: Stockholder, EVO Worldwide Stockholder, Medical Simulation Corporation Stockholder, EDDA Technology, Inc Stockholder, EnDepth Vision Systems, LLC Research Consultant, DxRay, Inc Advisor, RefleXion Medical Inc

Michael Walter Vannier MD, Abstract Co-Author: Nothing to Disclose

Intranasal (IN) drug administration provides a promising alternative to systemic administration since a direct anatomic pathway exists between the olfactory neuroepithelium of the nasal cavity and the brain. Several drugs have already been approved for IN application (e.g., oxytocin in autism), and others may be approved in the near future. Since little is known about the spatial and temporal characteristics of IN drug  delivery, a method of localizing their presence in the brain of a living animal is needed. 1. Nanotheranostics, the combination of diagnostic and therapeutic function in a single system through nanotechnology, has the potential to improve drug administration in the central nervous system. 2. MRI and CT-PET are becoming key tools in nanotheranostics since they can help determine the fate of nanoparticles containing drugs in the brain. 3. A major advantage of in vivo imaging in experimental IN delivery is its noninvasive nature and potential repeatability without the need for sacrificing animals. Thus, this imaging technology can be more easily translatated to humans. 

1. Nanotheranostics. 3. What's in a nanoparticle? 4. The nose to brain route. 4.  CT-PET, MRI and their application to small animal drug delivery. 5. From benchtop to the bedside. 6. The future of nanotheranostics.

http://abstract.rsna.org/uploads/2014/14002661/14002661_va4a.pdf

Veronesi, M, Cheng, S, Tsai, H, Zhang, H, Zamora, M, Vosicky, J, Mustafi, D, Fan, X, Lo, L, Chen, C, Vannier, M, Imaging of Drugs in the Brain Following Intranasal Delivery.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14002661.html